United States v. Glaxo Group Ltd.

United States v. Glaxo Group Ltd., 410 U.S. 52 (1973), is a 1973 decision of the United States Supreme Court in which the Court held that (1) when a patent is directly involved in an antitrust violation, the Government may challenge the validity of the patent; and (2) ordinarily, in patent-antitrust cases, "[m]andatory selling on specified terms and compulsory patent licensing at reasonable charges are recognized antitrust remedies." == Background == Imperial Chemical Industries (ICI) and Glaxo Group Ltd.

Source: Wikipedia — United States v. Glaxo Group Ltd. (CC BY-SA 4.0)

United States v. Glaxo Group Ltd.

United States v. Glaxo Group Ltd., 410 U.S. 52 (1973), is a 1973 decision of the United States Supreme Court in which the Court held that (1) when a patent is directly involved in an antitrust violation, the Government may challenge the validity of the patent; and (2) ordinarily, in patent-antitrust cases, "[m]andatory selling on specified terms and compulsory patent licensing at reasonable charges are recognized antitrust remedies." == Background == Imperial Chemical Industries (ICI) and Glaxo Group Ltd.

This neuron ends here.

Source: Wikipedia "United States v. Glaxo Group Ltd." · CC BY-SA 4.0

Share this article: X · Bluesky
Privacy Policy